Considerable research on PGC1α in diabetes type 2 (DM2) has shown that although its high expression is beneficial in certain tissues it is deleterious in others, rendering PGC1α difficult to target pharmaceutically [21]. This evidence concerns the gene PPARGC1A and myotonic dystrophy type 2.